Mar 20, 2023 | Press Releases
Accretive acquisition expected to add significant scale to INVO’s operations Contributes over $5 million in incremental annual revenue as well as positive net income Initial transaction that establishes acquisitions as 3rd key aspect of INVO’s commercial...
Jan 5, 2023 | Press Releases
SARASOTA, Fla., Jan. 5, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the...
Jan 3, 2023 | Press Releases
Shelly W. Holmström, M.D. FACOG, to serve as physician operator at soon to be opened Tampa-based INVO Center.The current metro area population of Tampa in 2022 is 2,945,000.INVO Centers focus on serving patients in need of advanced fertility care utilizing the...
Nov 30, 2022 | Press Releases
Patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (cIVF) in Malaysia INVOcell provides an advanced, effective and affordable infertility treatment option to help increase access to care. The multi-billion-dollar global...
Nov 14, 2022 | Press Releases
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., Nov. 14, 2022 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a commercial-stage fertility company focused on expanding access to advanced treatment...
